Quantitative high throughput screening (qHTS) of mitochondrial membrane potential and cell viability multiplex assay
HepG2 cells were dispensed at 2000 cells/4 µL/well in tissue culture treated 1536-well black wall/clear bottom assay plates (Greiner Bio-One North America, Monroe, NC, USA) using a Multidrop Combi Reagent Dispenser (Thermo Fisher, Waltham, MA, USA). Following incubation of the assay plates at 37°C overnight under a humidified atmosphere and 5% CO 2 in the robotic system incubator (Thermo Fisher), 23 nL of compound or DMSO was transferred into assay plates using a pin tool (Wako, Richmond, VA, USA). All of the compounds were screened at 15 concentrations ranging from 1.18 nM to 92.2 µM. The final concentration of DMSO in the assay was 0.45%. After treatment for 1 hr, 4 µL of 2X m-MPI reagent (1/500 dilution of Mito-MPS solution in assay buffer) was added into the wells using a Flying Reagent Dispenser (FRD) (Aurora Discovery, San Diego, CA, USA) and the plates were incubated for an additional 30 min at 37°C. Fluorescence intensities (485 nm excitation/535 nm emission for green fluorescent monomers; 540 nm excitation/590 nm emission for red fluorescent aggregates)
were measured using an Envision plate reader (PerkinElmer; Shelton, CT, USA) (Attene-Ramos et al. 2013; Sakamuru et al. 2012) . Data were expressed as the ratio of 590 nm/535 nm, an indicator of MMP. Immediately after, 2 µL of CellTiter-Glo® reagent was added, plates were incubated at room temperature for 30 min, and the luminescence intensity of each well was determined using a ViewLux plate reader (PerkinElmer).
qHTS data analysis
Briefly, raw plate reads for each titration point were first normalized relative to the positive control compound (0%) and DMSO-only wells (-100%) as follows: % Activity = [(V compound -V DMSO )/(V pos -V DMSO )] x 100, where V compound denotes the compound well value, V pos denotes the median value of the positive control wells, and V DMSO denotes the median values of the DMSO-only wells, and then corrected by applying a NCGC in-house pattern correction algorithm (Southall et al. 2009 ) using compound-free control plates (i.e., DMSO-only plates) at the beginning and end of the compound plate stack. Concentration-response titration points for each compound were fitted to a four-parameter Hill equation (Hill 1910 ) yielding concentrations of half-maximal activity (AC50) and maximal response (efficacy) values. Compounds were designated as Class 1-4 according to the type of concentration-response curve observed (Huang et al. 2011; Inglese et al. 2006) . Curve classes are heuristic measures of data confidence, classifying concentration-responses on the basis of efficacy, the number of data points observed above background activity, and the quality of fit. The curve sign describe the type of response.
Inhibitory curves described compounds that decreased the MMP (antagonist) and active curves were associated with compounds that increase the MMP (agonist) (Huang et al. 2011 ). All concentration response data and final activity calls are publicly available through PubChem 
Reproducibility call
Substances were first assigned an activity outcome based on their curve class. Activity outcomes:
inactive (class 4), active agonist/antagonist (class 1.1, 2.1), agonist/antagonist (class 1.2, 2.2), inconclusive agonist/antagonist (all other cases). Each activity outcome category was then assigned a score. Activity outcome scores: Active agonist (3), agonist (2), inconclusive agonist (1), active antagonist (-3), antagonist (-2), inconclusive antagonist (-1), inactive (0). The pair-wise activity outcome score differences for all replicates of each substance were then averaged and the % of inactive calls for the substance calculated to determine the final reproducibility call of the substance. Average pair-wise score difference: active match (<1.1, %inactive call <25%), inactive match (<1.1, %inactive call >50%), mismatch (>2.5), inconclusive (all other cases). Figure S1 . qHTS MMP assay plate map showing the location of the controls used in the screen. 
